Cargando…

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

Detalles Bibliográficos
Autores principales:	Barbui, T, Vannucchi, A M, Buxhofer-Ausch, V, De Stefano, V, Betti, S, Rambaldi, A, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, M L, Bertozzi, I, Gisslinger, H, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Falcone, C, Tefferi, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670947/ https://www.ncbi.nlm.nih.gov/pubmed/26617062 http://dx.doi.org/10.1038/bcj.2015.94

Ejemplares similares

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2020)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
por: Tefferi, A, et al.
Publicado: (2013)

Essential thrombocythemia treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

PB2214: CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
por: Tosoni, Luca, et al.
Publicado: (2023)

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
por: Carobbio, Alessandra, et al.
Publicado: (2020)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2023)

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2016)

Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia
por: Buxhofer‐Ausch, Veronika, et al.
Publicado: (2020)

Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2017)

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
por: Schalling, Martin, et al.
Publicado: (2017)

The new WHO classification for essential thrombocythemia calls for revision of available evidences
por: Barbui, Tiziano, et al.
Publicado: (2020)

Personalized management of essential thrombocythemia—application of recent evidence to clinical practice
por: Tefferi, A, et al.
Publicado: (2013)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
por: Mora, Barbara, et al.
Publicado: (2019)

Essential Thrombocythemia in Children and Adolescents
por: Putti, Maria Caterina, et al.
Publicado: (2021)

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
por: De Stefano, Valerio, et al.
Publicado: (2018)

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
por: De Stefano, Valerio, et al.
Publicado: (2018)

Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival
por: Gangat, Naseema, et al.
Publicado: (2022)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events
por: Gangat, Naseema, et al.
Publicado: (2022)

Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
por: Tosetto, Alberto, et al.
Publicado: (2021)

Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
por: Barbui, Tiziano, et al.
Publicado: (2019)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
por: Ferrari, Alberto, et al.
Publicado: (2019)

Systemic Mastocytosis and Essential Thrombocythemia: Case Report and Literature Overview
por: Cancian, Mauro, et al.
Publicado: (2019)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
por: Tefferi, Ayalew, et al.
Publicado: (2021)

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Prefibrotic myelofibrosis: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
por: Cerquozzi, S, et al.
Publicado: (2015)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

The functional −1019C/G HTR1A polymorphism and mechanisms of fear
por: Straube, B, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jabm1e7bg7r54uo0k6ks8iuc0t